Androgen News and Research

RSS

Sheep model may help address fertility problems in women

A Texas A&M AgriLife study with sheep may soon help address fertility problems in women, if it can discover ways to break the chain of generational transfer of polycystic ovary syndrome, PCOS -- one of the most common infertility disorders.

23 Feb 2021

Targeting MAPK4 enzyme may be a potential new strategy to combat prostate cancer

The battle against late-stage prostate cancer might have found a potential new strategy to combat this deadly disease.

20 Feb 2021

Could spironolactone treat COVID-19-related pneumonia and pulmonary fibrosis?

Researchers have described the potential of the drug spironolactone, a potassium-sparing diuretic, and anti-androgen, in preventing or alleviating the severity of COVID-19 pneumonia, and in preventing pulmonary fibrosis.

27 Jan 2021

Study finds new evidence about the positive role of androgens in breast cancer treatment

Researchers at the University of Adelaide have found new evidence about the positive role of androgens in breast cancer treatment with immediate implications for women with estrogen receptor-driven metastatic disease.

18 Jan 2021

Researchers discover unexpected role for the clock gene in prostate cancer progression

Our biological or circadian clock synchronizes all our bodily processes to the natural rhythms of light and dark. It's no wonder then that disrupting the clock can wreak havoc on our body.

15 Jan 2021

Inflammation marker linked to increased fatigue in prostate cancer patients treated with ADT

Prostate cancer is one of the most common cancers among men in the U.S. For many patients, hormone therapy is a treatment option.

4 Jan 2021

Researchers have a promising lead on COVID-19 treatment

By taking a lesson from prostate cancer, researchers now have a promising lead on treatment for COVID-19. Two proteins, ACE2 and TMPRSS2, help the coronavirus gain entry and replicate within cells. TMPRSS2 is well-known to Arul Chinnaiyan, M.D., Ph.D. His lab discovered that TMPRSS2 fuses with the ETS gene to drive more than half of all prostate cancers. They also knew that TMPRSS2 was regulated by the androgen receptor.

21 Dec 2020

FDA approves first oral drug for treating adult patients with advanced prostate cancer

Today, the U.S. Food and Drug Administration approved Orgovyx (relugolix) for the treatment of adult patients with advanced prostate cancer.

18 Dec 2020

Low testosterone can increase risk of severe COVID-19 in males

Researchers from the USA and Saudi Arabia describe the direct correlation between testosterone levels, inflammatory cytokines, disease progression, and worse outcomes in male COVID-19 patients.

4 Dec 2020

CRYM protein counteracts the growth of prostate tumors

Prostate cancer is caused by elevated hormone levels, and tumors are generally treated using hormone therapy. However, after some time, tumor growth is no longer dependent on hormones, which results in resistance to treatment. As a result, new types of treatments are urgently needed.

18 Nov 2020

Gene signature may help develop new therapies against advanced prostate cancer

Researchers have identified a genetic signature in localized prostate cancer that can predict whether the cancer is likely to spread, or metastasize, early in the course of the disease and whether it will respond to anti-androgen therapy, a common treatment for advanced disease.

11 Nov 2020

Two paralogous androgen receptor genes control social dominance

Rank in social hierarchy is a condition not solely claimed by humans. In the animal kingdom, male peacocks exhibit brightly colored plumes to illustrate dominance, and underwater, male fish show pops of bright colors to do the same.

11 Nov 2020

Reducing the airborne transmission risk for SARS-CoV-2

Rapid Reviews: COVID-19 (RR:C19), an open-access overlay journal published by the MIT Press that accelerates peer review of COVID-19-related research preprints, is currently soliciting reviews of the following COVID-19 preprints.

6 Nov 2020

Researchers identify a novel vulnerability in advanced prostate cancer

Researchers at the University of Bern led an international team that has identified a novel vulnerability in advanced prostate cancer that is no longer responding to hormonal therapy.

3 Nov 2020

Researchers report outcomes of salvage low dose RT brachytherapy after EBRT for prostate cancer

Researchers involved in the phase II NRG Oncology RTOG 0526 trial studying low dose rate (LDR) prostate brachytherapy (BT) following local recurrence (LR) after external beam radiotherapy (EBRT) for patients with low-to-intermediate risk prostate cancer reported late Grade 3 gastrointestinal and genitourinary adverse events (AEs) occurring in 14% of trial participants.

28 Oct 2020

Androgen deprivation strategies could help mitigate SARS-CoV-2 infection

Since the beginning of the COVID-19 pandemic, researchers have noted that women are generally less severely affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This has led to the exploration into estrogen and androgens' role in the hyperinflammatory clinical phenotypes of COVID-19. A recent study published on the preprint server bioRxiv shows that drugs targeting androgens and TMPRSS2 inhibitors may potentially combat the pandemic.

20 Oct 2020

A global review of COVID-19 impact on cancer treatment and research

The COVID-19 pandemic has impacted virtually every aspect of cancer care and research- from introducing new risks for cancer patients to disrupting the delivery of cancer treatment and the continuity of cancer research, a review of scientific literature shows.

7 Oct 2020

Gut bacteria may play a role in prostate cancer therapies

A new study from Lawson Health Research Institute and Western University illustrates how the gut microbiome interacts with an oral medication in prostate cancer patients, suggesting bacteria in the gut play a role in treatment outcomes.

30 Sep 2020

UTHSC professor receives $455,000 grant to study cause of aggressive prostate cancer

Ramesh Narayanan, PhD, professor in the Department of Medicine and the Division of Hematology and Oncology at the University of Tennessee Health Science Center, has received a $455,000 grant from the National Cancer Institute for a two-year study of the underlying cause of the development of aggressive prostate cancer in African American men.

17 Sep 2020

Enzalutamide has added benefit for men with castration-resistant prostate cancer at high risk of metastasis

In 2018 and 2019, the German Institute for Quality and Efficiency in Health Care already investigated whether the drug enzalutamide has an advantage in comparison with the appropriate comparator therapy, i.e. in comparison with watchful waiting while maintaining ongoing conventional androgen deprivation therapy (ADT), for adult men with high-risk non-metastatic castration-resistant prostate cancer.

19 Aug 2020